Ipsen has agreed to acquire Canadian clinical stage pharma company ‘Clementia’ for $1.04bn, plus a contingent payment of $263m (upon achievement of a future regulatory milestone). Clementia’s key asset is palovarotene (retinoic acid receptor gamma selective agonist) which is currently being evaluated for the treatment of two rare bone disorders – fibrodysplasia ossificans progressive/FOP (abnormal growth of bone in muscles and connective tissues) and multiple osteochon
26 Feb 2019
Clementia bolsters Ipsen’s rare disease portfolio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Clementia bolsters Ipsen’s rare disease portfolio
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
26 Feb 2019 -
Author:
Sumit Sayal -
Pages:
3
Ipsen has agreed to acquire Canadian clinical stage pharma company ‘Clementia’ for $1.04bn, plus a contingent payment of $263m (upon achievement of a future regulatory milestone). Clementia’s key asset is palovarotene (retinoic acid receptor gamma selective agonist) which is currently being evaluated for the treatment of two rare bone disorders – fibrodysplasia ossificans progressive/FOP (abnormal growth of bone in muscles and connective tissues) and multiple osteochon